Lovenox Dosing in Patients with Elevated BMI

Primary Recommendation

• The European Society of Cardiology recommends that for patients with obesity (BMI ≥30), standard fixed-dose enoxaparin (40 mg once daily) for VTE prophylaxis is inadequate and weight-based dosing should be used, while therapeutic dosing requires careful monitoring with anti-Xa levels to avoid both under- and over-anticoagulation 1, 2

VTE Prophylaxis Dosing by Obesity Class

• For patients with obesity class 1-2 (BMI 30-40), the European Heart Journal recommends enoxaparin 40 mg subcutaneously twice daily for VTE prophylaxis 1, 2
• For patients with obesity class 3 (BMI ≥40) or weight >120 kg, the European Heart Journal recommends enoxaparin 0.5 mg/kg subcutaneously twice daily for VTE prophylaxis 1, 2
• The American College of Cardiology recommends considering measuring anti-Xa activity (target 0.2-0.4 IU/mL) to ensure adequate prophylaxis in patients with obesity class 3 (BMI ≥40) or weight >120 kg 1, 2

Therapeutic Anticoagulation Dosing

• The American Heart Association recommends enoxaparin 1 mg/kg subcutaneously every 12 hours as the starting dose for therapeutic anticoagulation in patients with obesity 3, 4, 5, 6, 7
• The European Heart Journal recommends dose reduction by approximately 20% in patients with BMI >40 to avoid supratherapeutic levels 1
• The European Heart Journal recommends anti-Xa monitoring in obesity class ≥3 (target peak 0.5-1.0 IU/mL) 1, 2

Monitoring Strategy

• The European Heart Journal recommends monitoring anti-Xa levels in patients with obesity class ≥3 (BMI ≥40) receiving either prophylactic or therapeutic dosing 1, 2
• The American College of Cardiology recommends monitoring anti-Xa levels in patients with weight >120 kg on any enoxaparin regimen 1, 2

Special Populations

• The European Heart Journal recommends reduced fixed dosing for severe underweight patients (BMI <18.5 or weight <60 kg) 1, 2
• The American College of Cardiology recommends considering monitoring anti-Xa activity in severe underweight patients to avoid over-anticoagulation 1, 2
• The American Heart Association recommends enoxaparin 1 mg/kg once daily (instead of twice daily) for therapeutic dosing in patients with CrCl <30 mL/min 8
• The European Heart Journal recommends careful anti-Xa monitoring in patients with the combination of obesity and renal impairment 1, 8